This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
GB-115
Russian dipeptide CCK-B receptor antagonist developed at the Zakusov Institute (Seredenin / Garibova lab).
Aliases (4)
Overview
What is GB-115?
GB-115 is a Russian-developed dipeptide derivative of cholecystokinin-4 (CCK-4) tetrapeptide, designed as an anxiolytic and antidepressant. It is in research/clinical phases in Russia and not approved in Western markets.
Key Benefits
Reported anxiolytic and antidepressant effects in Russian preclinical and early clinical trials. Anecdotal nootropic use for anxiety reduction without sedation. Limited Western data.
Mechanism of Action
Acts as a CCK-B receptor antagonist, blocking the anxiogenic effects of endogenous CCK-4. Also modulates dopaminergic and serotonergic transmission. Mechanism is broadly inverse of panic-inducing CCK-B agonism.
Quality Indicators
Sterile pre-filled spray
Spray bottles should be sealed, sterile, and labeled with concentration.
Refrigeration required
Most intranasal peptides require fridge storage; a warm bottle suggests degraded peptide.
Cloudy or discolored liquid
Cloudiness or color change indicates degradation or contamination.
What to Expect
- Day 1-7Injection / administration protocol established. Tolerability check.
- Week 2-4Early onset of effect — subtle in most users, noticeable in responders.
- Week 4-8Peak benefit window for most peptide cycles.
- Week 8+Cycle decision point: continue, taper, or break.
Side Effects & Safety
- Common (>10% users): Reported as minimal in Russian sources. Possible mild headache, mild GI discomfort.
- Less common (1-10%): Sparse data; Russian sources report negligible adverse events in small clinical samples.
- Rare-serious (<1%): No documented serious organ toxicity, dependence, withdrawal, or abuse pattern in available literature. Caveat: the absence of evidence reflects sparse study volume, not necessarily a clean safety signature. Long-term safety in healthy users is essentially uncharacterized.
- Specific watch periods: Unstudied. If used, treat as research-chem and run baseline labs + 4-week / 12-week follow-up (LFTs, CBC, kidney panel) at minimum.
References
Cholecystokinin (CCK) receptor antagonists in panic disorder — Western pharmacology context
background on the broader CCK-B antagonist class and its Western Phase II trial history
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.